Perkins Coie’s business lawyers work with emerging and established life sciences companies in the United States and abroad in a variety of areas, including:  

• Choice of entity, corporate formation and structure, corporate governance, and public reporting. 
• Raising capital, including venture capital, private/preferred stock investments, debt financings, initial public offerings, and subsequent equity follow-on financings. 
• Due diligence, mergers, and acquisitions. 
• Corporate partnering, complex licensing, strategic alliances, technology agreements, research and development collaborations, joint ventures, and supply and distribution agreements. 
• Business model counseling, IP strategy, and the U.S. Food and Drug Administration approval process. 
• Executive compensation and equity incentive arrangements. 
• Real estate and land use matters. 

Many of our team members hold degrees in molecular biology, chemistry, or biophysics and bring with them diverse experiences from both the life sciences industry. We offer comprehensive services to biotechnology, medical device, and pharmaceutical enterprises in the following areas:  

• Patent portfolio management and patent procurement. 
• Opinions on patentability, patent infringement, validity, freedom to operate, and design-around issues. 
• Patent litigation to enforce rights or defend against infringement claims. 
• Post-grant proceedings under the America Invents Act, including inter partes review, reexaminations, and reissues. 
• International Trade Commission Chapter 337 actions.

Our commitment to our clients has enabled us to become experts in a wide range of emergent technologies. This experience translates to the creation of high-quality patents and the development of strategic patent portfolios that align with our clients' business objectives. Our areas of focus include: 

• Artificial intelligence and machine learning diagnostic tools, drug discovery, and related health services. 
• Antibody, peptibody, and ADC therapeutics and diagnostics. 
• Biologics and biosimilars. 
• Cellular therapeutics. 
• Diagnostics. 
• Drug discovery, development, and formulation. 
• Gene editing, including CRISPR technology. 
• Gene therapy, including nonviral and viral gene delivery. 
• Genetic testing, including cfDNA diagnostics and NIPT. 
• Genetically engineered cells and microorganisms. 
• Immunology, including autoimmune treatment and diagnostics. 
• Immunotherapy, including CAR-T and TCR therapy. 
• Microfluidics, microplates, and microarrays. 
• Nanotechnology. 
• Nucleic acid sequencing and multiplex screening. 
• NexGen sequencing. 
• Oncology. 
• Peptide design and therapeutics. 
• Protein identification, characterization, and therapeutics. 
• Personalized medicine/precision medicine. 
• Pharmaceuticals. 
• Small molecule identification, synthesis, and therapeutics. 
• Stem cell generation, modification, and therapy. 
• Targeted drug delivery. 
• Viral diagnostics, therapeutics, and vaccines, including for COVID-19. 

• U.S. News—Best Lawyers® ranked Nationally in the area of Biotechnology Law, 2013—2020 
• Chambers USA for life sciences in California, 2013-2024 
• Chambers Asia-Pacific as a “recognized firm” in life sciences, 2013-2015 
• Ranked by Lake Whillans “Top 10 Life Sciences Law Firms” for patents, 2016-2017